TAILIEUCHUNG - Assesment of treatment of prostate cancer by endocrine therapy at 103 Military Hospital

To evaluate the results of treatment of prostate cancer by endocrine therapy. Subjects and methods: All cases with prostate cancer were diagnosed by histopathology, treated by endocrine. Evaluating the results after 3 months, 6 months, and over 1 year. | Journal of military pharmaco-medicine no1-2019 ASSESMENT OF TREATMENT OF PROSTATE CANCER BY ENDOCRINE THERAPY AT 103 MILITARY HOSPITAL Nguyen Anh Tuan1; Tran Van Hinh1; Pham Quang Vinh1; Nguyen Phu Viet1 Dao Van Nhat1; Nguyen Dinh Duong1; Cao Quyet Thang1; Le Anh Tuan1 SUMMARY Objectives: To evaluate the results of treatment of prostate cancer by endocrine therapy. Subjects and methods: All cases with prostate cancer were diagnosed by histopathology, treated by endocrine. Evaluating the results after 3 months, 6 months, and over 1 year. Results: After endocrine therapy over 12 months, PSA total level 10 ng/mL: . PSA total level decreased from ± ng/mL to ± ng/mL (p 10 ng/mL (). The total PSA level decreased from ± ng/mL to ± ng/mL, significantly different with p 10 ng/mL; there are distant metastases. * Data processing: + Diagnosed finally prostate cancer by histopathology. Data were entered and processed by statistical software in SPSS and Excel 2010. + Used endocrine agents with enough dose and times at 103 Military Hospital. RESULTS AND DISCUSSION + Full documentation of clinical, treatment and development during hospitalization. - Exclusion criteria: + Patients do not agree to enroll in the study. + Patients who are diagnosed with histopathology and treatment by other medical centers. Patients diagnosed with prostate cancer without histologic results, incomplete records of treatment and follow-up. 2. Methods. - Case, description study. - Process: Patients were diagnosed with prostate biopsy on histopathology, histopathological classification, Gleason score, blood PSA level before and after endocrine treatment 3 months, 6 months and over 1 year. - Endocrine agents: Diphereline mg every 3 months. 146 1. Characteristics of patients. * Age of patients (n = 48): 80 years old: 17 patients (). The mean age of patients with prostate cancer in this study was ± . The youngest was 48, the .

• Y khoa - Dược
• Prostate cancer
• Endocrine therapy
• Hormone treatment
• Cancer patients treated
• Localized prostate cancer
• Cancer surveillance series
• Radiation therapy
• Clinical management
• Metastatic prostate cancer
• BMC Cancer
• Initial prostate biopsy
• Diagnose prostate cancer
• Probability density functions
• Adenocarcinoma of prostate
• Androgen independent prostatic cancer
• Docetaxel resistance
• Anti neoplastic agent resistance
• Doctor of Medicine summary
• Application of 12 core prostate biopsy
• Transrectal ultrasound guidance
• Diagnosis of prostate cancer
• Castration resistant prostate cancer
• Androgen concentrations
• Measure testosterone
• Chromosomal instability
• Prostate needle biopsies
• Amino acids
• Prostate cancer biomarkers
• Prostate specific antigen
• Diagnostic biomarkers
• Biological fluids
• Metastatic castrate resistant
• Prostate specific antigen while
• Health implications
• GnRH antagonist
• GnRH agonist
• Neoadjuvant androgen deprivation therapy
• Quality of life
• Non invasive biomarkers
• Benign prostate hyperplasia
• Diagnostic dilemma
• Prostate specific antigen doubling time
• Personalized peptide vaccine
• Surrogate marker
• Overall survival
• Recombinant antibody
• Human dendritic cells
• The medical doctoral thesis
• Histopathological fearures immunohistochemistry
• Methylation of rassf1a gene in prostate cancer
• Rassf1a gene in prostate cancer
• Istopathological features in prostate carcinoma
• Genome Biology
• DNA methylation
• Slow growing prostate cancer
• Prostate specifc antigen decline rate per week
• Degree of prostatic collapse
• Tissue signal rate of prostate
• Prostatitis disease
• Cell migration
• Cell invasion
• Above mentioned cytokines
• High cancer related deaths
• Prostate intraepithelial neoplasia
• PSGR protein
• Cancer cell growth
• Regulatory T cell
• Platinum based chemotherapy
• Multiple cancer cell lines
• Anti prostate cancer
• Frequently diagnosed cancer
• PC3 cell migration
• Human prostate cancer
• Breast and prostate cancer
• Expression of NRIF3
• Breast cancer
• Transcriptional repressor
• Targeted imaging
• Orthotopic prostate cancer
• Clinical transformable
• Photoacoustic imaging system
• Meta analysis
• Precise mechanism
• Tumor cells
• Recurrent prostate cancer
• Salvage radiation therapy
• High risk prostate cancer
• Primary hypothesis
• Protein tyrosine phosphatase non receptor 12
• Quantitative Gleason grade